Skip to content

Monte Rosa Therapeutics, Inc.

GLUE

CIK 0001826457

← back to feed
Revenue (TTM)
$125.1M
+63.5% YoY Q1 May 2026
Net Income (TTM)
−$36.99M
+46.9% YoY Q1 May 2026
EPS Diluted (TTM)
—
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-43.6%
Q1 May 2026
Net Margin
-29.6%
Q1 May 2026
Free Cash Flow (TTM)
−$158.45M
Q1 May 2026
Cash
$159.86M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
84.48M sh
Q1 May 2026

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings